Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "Huntington's Disease - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Huntington's disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
"Huntington's disease- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Huntington's disease pipeline landscape is provided which includes the disease overview and Huntington's disease treatment guidelines. The assessment part of the report embraces, in depth Huntington's disease commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Huntington's disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Huntington's disease R&D. The therapies under development are focused on novel approaches to treat/improve Huntington's disease.
Huntington's disease Emerging Drugs Chapters
This segment of the Huntington's disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Huntington's disease Emerging Drugs
Pridopidine: Prilenia Therapeutics
Pridopidine is an oral drug currently in development for the treatment of Huntington's disease and ALS. It is administered in a small easy-to-swallow capsule twice a day. Multiple clinical studies have been conducted providing important understanding about pridopidine's safety, mechanism of action, and efficacy.
Activation of the S1R by pridopidine enhances the clearance of toxic proteins, enhances energy production, and reduces cellular stress and inflammation. Studies in animal models and human cells show that pridopidine prevents neuronal cell death, and strengthens and enhances the connections between neurons. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Huntington's disease.
ANX005: Annexon
ANX005 is a humanized IgG4 monoclonal antibody that binds with high affinity to the complement C1q protein and inhibits initiation of the classical complement cascade. Given by intravenous infusion, the antibody is in development to treat autoimmune and neurodegenerative disorders. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Huntington's disease.
LPM3770164: Luye Pharma
LPM3770164 is a drug candidate being developed by Shandong Luye Pharmaceutical Co., Ltd. It is a VMAT2 inhibitor, which is a type of medication that targets the vesicular monoamine transporter 2 (VMAT2) protein. Currently, the drug is in the Phase I stage of development to treat Huntington's disease.
Huntington's disease: Therapeutic Assessment
This segment of the report provides insights about the different Huntington's disease drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Huntington's disease
There are approx. 20+ key companies which are developing the therapies for Huntington's disease. The companies which have their Huntington's disease drug candidates in the most advanced stage, i.e. Phase III include, Prilenia Therapeutics.
Key Questions
- How many companies are developing Huntington's disease drugs?
- How many Huntington's disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Huntington's disease?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Huntington's disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Huntington's disease and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Prilenia Therapeutics
- Annexon
- Luye Pharma
- Sage Therapeutics
- Wave Life Sciences
- UniQure Biopharma
- Medesis Pharma
- Spark therapeutics
- ExoRNA Bioscience
Key Products
- Pridopidine
- ANX005
- LPM3770164
- SAGE-718
- WVE003
- AMT 130
- Nano P42T
- Huntington's Disease therapy
- ER2001
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Huntington's disease Report Insights
- Huntington's disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Huntington's disease Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/gafpz1
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
